Published in Gene Therapy Weekly, January 27th, 2005
Revenue for the third quarter was $11.0 million, compared to $12.8 million for the same period a year ago. For the first 9 months of 2004, revenue was $30.9 million, compared to $35.1 million for the first 9 months of 2003. These figures reflect the long-term, product development focus of the company's business strategy, as well as the timing of milestone payments.
At the close of the third quarter the company had $16.1 million in deferred research revenue, compared to $13.5 million at the close of the third quarter 2003....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly